CF PHARMTECH (02652) expects to achieve a adjusted net profit of approximately 30-35 million yuan in 2025, with stable business operations and continuous progress in innovative research and development.

CF PHARMTECH (02652) announced that the overall business operations of the group are running normally, maintaining profitability for three consecutive years. The group is expected to achieve the following in 2025: (i) revenue between RMB 410 million and 450 million; (ii) net profit attributable to shareholders between RMB 2 million and 3 million in accordance with International Financial Reporting Standards (IFRS); and (iii) adjusted net profit (non-IFRS indicator) between RMB 30 million and 35 million. Since its listing, the group has achieved several key milestones in the application of innovative drugs and completed brand reporting of products in the national centralized procurement program for medical institutions to address market challenges and drive sustainable growth: (a) applications for the approval of the listing of Budesonide nasal spray and new drug clinical trials for ICF004 and ICF001 have been accepted by the China National Medical Products Administration; in addition, the clinical trial application for Oxymetazoline Mometasone nasal spray has also been approved, strengthening the group's product lineup in the respiratory and nasal care field; (b) brand reporting for CF017 (Inhaled Budesonide Suspension) in medical institutions has been completed as part of the national VBP update plan, with hospital coverage expanded nationwide and procurement cycle extended until the end of 2028; (c) the company has been included in the Hang Seng Composite Index and the list of securities eligible for the Stock Connect schemes, which is expected to enhance the liquidity of the H shares; (d) based on the general authorization granted in December 2025, the company has conducted several H share repurchases. The company may consider further repurchasing H shares based on market conditions and capital arrangements, while complying with listing rules and applicable regulations.